Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 8/20 | 0.70 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.57 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28209867 | 1.00 | NPC1 (0.74) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Bromide SCHEMBL28209866 | 1.00 | NPC1 (0.74) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Bromide SCHEMBL28286655 | 0.98 | NPC1 (0.72) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Bromide SCHEMBL28286654 | 0.98 | NPC1 (0.72) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| SCHEMBL2210517 | 0.98 | NPC1 (0.77) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Hydrochloric Acid SCHEMBL1219233 | 0.96 | NPC1 (0.74) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Hydrochloric Acid SCHEMBL8698166 | 0.96 | NPC1 (0.74) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Hydrochloric Acid SCHEMBL8698170 | 0.96 | NPC1 (0.74) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| SCHEMBL23625647 | 0.94 | NPC1 (0.71) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| SCHEMBL23625628 | 0.92 | NPC1 (0.69) | NPC1ABCG2RAB9ACHRNB2CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 799 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116448746-A | Quick identification kit for unfrozen meat and application thereof | 南京农业大学 | 2023-07-18 | — | — | CN | claimed |
| CN-114921520-A | Method for measuring induction effect of niclosamide on cell cycle arrest and apoptosis | 邵阳学院 | 2022-08-19 | — | — | CN | claimed |
| CN-110702675-B | Application of two-dimensional nano material as dehydrogenase | 苏州大学 | 2022-02-15 | — | — | CN | claimed |
| CN-107937483-A | STAT1 promoter methylations detect the application in cells of resistant tumors | 徐州医科大学 | 2018-04-20 | — | — | CN | claimed |
| US-20260146070-A1 | FUNCTIONALLY MODIFIED MAYTANSINOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| CN-122075534-A | Application of Fe/Mn bimetallic enzyme in preparation of periodontitis resisting preparation or tooth whitening preparation | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026106127-A1 | LACTICASEIBACILLUS PARACASEI HP7 USEFUL FOR GASTROINTESTINAL HEALTH WITH PREVENTIVE OR ALLEVIATIVE EFFICACY FOR FUNCTIONAL DYSPEPSIA AND USES THEREOF | 주식회사 에치와이 | 2026-05-21 | — | — | WO | disclosed |
| CN-120757483-B | Mitochondrion targeting fluorescent probe and preparation method and application thereof | 河南省人民医院 | 2026-05-12 | — | — | CN | disclosed |
| CN-122005320-A | Centella asiatica extract-containing liposome composition and preparation method, preparation and application thereof | 广州青囊生物科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260115143-A1 | POLYMER DERIVATIVES AND THEIR USE AS LIPID NANOPARTICLE MODIFIERS | Université de Liège (BE) | 2026-04-30 | — | — | US | disclosed |
| EP-4725494-A1 | COMPOSITION AND METHOD FOR TREATING, PREVENTING, AND ALLEVIATING RESPIRATORY SYMPTOM OR DISEASE | Efil Bioscience Inc. (KR) | 2026-04-15 | — | — | EP | disclosed |
| EP-4720162-A1 | MAIN CHAIN CATIONIC OLIGO(IMIDAZOLIUM) FORMS N-HETEROCYCLIC CARBENE FOR EFFECTIVE BACTERIAL KILLING IN COMPLEX ENVIRONMENT | Nanyang Technological University (SG) | 2026-04-08 | — | — | EP | disclosed |
| US-6403555-B1 | TREATING INFLAMMATORY, AUTOIMMUNE DISEASES, INCLUDING GRAFT-VERSUS-HOST DISEASE AND ENHANCEMENT OF GRAFT/TISSUE SURVIVAL FOLLOWING TRANSPLANT | XCYTE THERAPIES, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020045575-A1 | Depsipeptide and congeners thereof for use as immunosuppressants | CELGENE CORPORATION | 2002-04-18 | — | — | US | disclosed |
| WO-2001042282-A1 | DEPSIPEPTIDE AND CONGENERS THEREOF FOR USE AS IMMUNOSUPPRESSANTS | XCYTE THERAPIES, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| US-6156302-A | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes | FORDHAM UNIVERSITY (US) | 2000-12-05 | — | — | US | disclosed |
| EP-1001029-A1 | Method for increasing sucrose content of plants | UNILEVER PLC (GB) | 2000-05-17 | — | — | EP | disclosed |
| EP-0912750-A1 | METHOD FOR INCREASING SUCROSE CONTENT OF PLANTS | UNILEVER PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001574-A1 | METHOD FOR INCREASING SUCROSE CONTENT OF PLANTS | UNILEVER PLC (GB) | 1998-01-15 | — | — | WO | disclosed |
| US-5126247-A | For enzymatic colorimatic measurement of presence or concentration of analytes in samples of animal fluids; medical diagnosis | ENZYMATICS, INC. (US) | 1992-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146070-A1 | FUNCTIONALLY MODIFIED MAYTANSINOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF | NOS1, NOS3, NOX5 | NPC1 387/4885ABCG2 454/4885RAB9A 698/4885 |
| US-20260115143-A1 | POLYMER DERIVATIVES AND THEIR USE AS LIPID NANOPARTICLE MODIFIERS | SGMS2, SGMS1, PHOSPHO1 | NPC1 111/4885ABCG2 3971/4885RAB9A 3089/4885 |
| US-20020045575-A1 | Depsipeptide and congeners thereof for use as immunosuppressants | IL2, CD22, HLA-DRB1 | NPC1 4009/4885ABCG2 3227/4885RAB9A 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.